The minimal residual disease (MRD) testing market — molecular diagnostic assays that detect trace, sub-clinical cancer cells or circulating tumor DNA remaining after treatment, often months befor...
The targeted sequencing and resequencing market — next-generation sequencing (NGS) workflows that focus on a defined, clinically relevant set of genes or genomic regions rather than sequencing an...
